GFA Production (Xiamen) Co., Ltd. Issues Voluntary Nationwide Recall of Easy Care First Aid® Burn Cream and First Aid Kits Due to Microbial Contamination
December 23, 2022
Olpruva receives FDA approval for patients with some urea cycle disorders (UCD’s)
December 27, 2022December 23, 2022 – Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy (semaglutide) injection 2.4 mg, making it the first-and-only prescription anti-obesity medicine for teens with once-weekly dosing.
Wegovy is now also indicated for use in adolescents (≥ 12 years old) with an initial BMI at or above the 95 th percentile for age and sex (based on CDC growth charts) along with a reduced calorie meal plan and increased physical activity to lose weight and keep it off.
Adolescents treated with Wegovy had greater incidences of gallbladder problems including gallstones, low blood pressure, rash, and itching compared to adults treated with Wegovy.
Do not use Wegovy if:
- You or any of your family have ever had medullary thyroid carcinoma.
- You have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- You have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy.